127094-57-9

Usage

Uses

Used in Pharmaceutical Synthesis:
EDCN is utilized as an intermediate in the synthesis of pharmaceutical drugs, contributing to the development of new medications with potential therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical industry, EDCN serves as an intermediate in the production of various agrochemicals, aiding in the creation of products designed to protect crops and enhance agricultural yields.
Used in Anti-inflammatory Applications:
EDCN has been studied for its potential anti-inflammatory properties, suggesting that it could be used in the development of treatments for inflammatory conditions.
Used in Anticancer Research:
EDCN is also being investigated for its potential anticancer properties, indicating that it may play a role in the development of cancer therapies in the future.

Upstream product

• 1184919-05-8 ethyl 6-bromo-4-hydroxy-1,5-naphthyridine-3-carboxylate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 1220700-73-1 diethyl 2-(((6-bromopyridin-3-yl)amino)methylene)malonate 
• 4487-59-6 2-bromo-5-nitropyridine 
• 124-40-3 dimethyl amine 
• 24362-46-7 diethyl 2-(ethoxymethylene)malonate 
• 13534-97-9 6-bromopyridine-3-amine 

Downstream Products

• 1416000-52-6 ethyl 6-chloro-4-((3-(trifluoromethyl)phenyl)amino)-1,5-naphthyridine-3-carboxylate 
• 1415999-78-8 2-(6-methoxypyridin-3-yl)-10-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1416000-69-5 tert-butyl 4-(4-(2-(6-methoxypyridin-3-yl)-9-oxopyrido[3,2-c][1,5]naphthyridin-10(9H)-yl)-2-(trifluoromethyl)phenyl)piperazin-1-carboxylate 
• 1416000-72-0 2-(4-((6-chloro-3-(hydroxymethyl)-1,5-naphthyridin-4-yl)amino) phenyl)-2-methylpropionitrile 
• 1416000-76-4 2-(4-(2-chloro-9-oxopyrido[3,2-c][1,5]naphthyridin-10(9H)-yl)phenyl)-2-methyl propanenitrile 
• 1415999-80-2 2-methyl-2-(4-(9-oxo-2-(quinolin-3-yl)pyrido [3,2-c][1,5]naphthyridin-10(9H)-yl)phenyl) propanenitrile 
• 1416000-79-7 tert-butyl 4-(4-(2-(6-aminopyridin-3-yl)-9-oxopyrido[3,2-c][1,5]naphthyridin-10(9H)-yl)-2-(trifluoromethyl)phenyl)piperazin-1-carboxylate 
• 1415999-82-4 2-(6-aminopyridin-3-yl)-10-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5]naphthyridin-9(10H)-one hydrochloride 
• 1415999-84-6 2-(4-(2-(6-aminopyridin-3-yl)-9-oxopyrido [3,2-c][1,5]naphthyridin-10(9H)-yl)phenyl)-2-methylpropanenitrile 
• 1415999-86-8 2-(4-(2-(6-methoxypyridin-3-yl)-9-oxopyrido [3,2-c][1,5]naphthyridin-10(9H)-yl)phenyl)-2-methylpropanenitrile 
• 1415999-92-6 N-(5-(9-oxo-10-(3-(trifluoromethyl)phenyl)-9,10-dihydropyrido[3,2-c][1,5]naphthyridin-2-yl) pyridin-2-yl)acetamide 
• 1416000-85-5 tert-butyl 3-(9-oxo-10-(3-(trifluoromethyl)phenyl)-9,10-dihydropyrido[3,2-c][1,5]naphthyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-1-carboxylate 
• 1415999-96-0 2-(1H-pyrrolo[2,3-b]pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 
• 1415999-98-2 2-(6-(hydroxymethyl)pyridin-3-yl)-10-(3-(trifluoromethyl)phenyl)pyrido[3,2-c][1,5] naphthyridin-9(10H)-one 

Relevant academic research and scientific papers

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat

BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS

The present invention relates to the technical field of medicine and pharmacy, and particularly relates to bicyclic group substituted pyrimidine compounds represented by general formula (I), pharmaceutical acceptable salts thereof or stereoisomers thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification. The present invention also relates to preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfuntion diseases and diseases with lower urinay tract symptoms.

THREE-RING PI3K AND/OR MTOR INHIBITOR

The present application relates to a compound as represented by general formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, preparation method of the compounds, a pharmaceutical composition containing the compounds, us

PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

THREE-RING PI3K AND/OR MTOR INHIBITOR

The present application relates to a compound as represented by general formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, preparation method of the compounds, a pharmaceutical composition containing the compounds, uses thereof in the preparation of drugs for treating and/or preventing proliferative diseases, and a method using the compounds to treat and/or prevent proliferative diseases. R1, R2, R3, R4, R5, R6, X, A and B in the formula are as defined in the specification.

Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design

PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncology. To search for a structurally differentiated back-up candidate to PF-04691502, which is currently in phase I/II clinical trials for treating solid tumors, a lead optimization effort was carried out with a tricyclic imidazo[1,5]naphthyridine series. Integration of structure-based drug design and physical properties-based optimization yielded a potent and selective PI3K/mTOR dual kinase inhibitor PF-04979064. This manuscript discusses the lead optimization for the tricyclic series, which both improved the in vitro potency and addressed a number of ADMET issues including high metabolic clearance mediated by both P450 and aldehyde oxidase (AO), poor permeability, and poor solubility. An empirical scaling tool was developed to predict human clearance from in vitro human liver S9 assay data for tricyclic derivatives that were AO substrates.

IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS

The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-Kalpha inhibitors and/or PI3- Kalpha/mTOR dual inhibitors